{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:32:46Z","timestamp":1789475566430,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-025-01922-2","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T02:46:10Z","timestamp":1756262770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Imeglimin as an effective therapeutic approach in management of type 2 diabetes mellitus: an umbrella review and systematic review, meta-regression and meta-analysis"],"prefix":"10.1186","volume":"17","author":[{"given":"Qian","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Mae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Kutbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Nasser","family":"AlJurayyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abu-Zaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parsa","family":"Jamilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Falahatzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"1922_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S2213-8587(18)30204-3","volume":"6","author":"AP Hills","year":"2018","unstructured":"Hills AP, Arena R, Khunti K, Yajnik CS, Jayawardena R, Henry CJ, et al. Epidemiology and determinants of type 2 diabetes in South Asia. Lancet Diabetes Endocrinol. 2018;6:966\u201378.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1922_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Reviews Endocrinol. 2018;14:88\u201398.","journal-title":"Nat Reviews Endocrinol"},{"key":"1922_CR3","unstructured":"Zhao Q, Peng C. The global burden of disease attributable to high fasting plasma glucose in 204 countries and territories, 1990\u20132021: A systematic analysis of the global burden of disease study 2021. Cheng, the global burden of disease attributable to high fasting plasma glucose in.204:1990\u20132021."},{"key":"1922_CR4","first-page":"102037","volume":"42","author":"B Gieroba","year":"2025","unstructured":"Gieroba B, Kryska A, Sroka-Bartnicka A. Type 2 diabetes mellitus \u2013 conventional therapies and future perspectives in innovative treatment. Biochem Biophys Rep. 2025;42:102037.","journal-title":"Biochem Biophys Rep"},{"key":"1922_CR5","unstructured":"Feingold KR. Oral and injectable (non-insulin) Pharmacological agents for the treatment of type 2 diabetes. Endotext [Internet]; 2024."},{"key":"1922_CR6","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.9778\/cmajo.20130073","volume":"2","author":"B Hemmingsen","year":"2014","unstructured":"Hemmingsen B, Schroll JB, Wetterslev J, Gluud C, Vaag A, Sonne DP, et al. Sulfonylurea versus Metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open. 2014;2:E162\u201375.","journal-title":"CMAJ Open"},{"key":"1922_CR7","doi-asserted-by":"publisher","first-page":"1132650","DOI":"10.3389\/fphar.2023.1132650","volume":"14","author":"K Mokgalaboni","year":"2023","unstructured":"Mokgalaboni K, Lebelo SL, Modjadji P, Ghaffary S. Okra ameliorates hyperglycaemia in pre-diabetic and type 2 diabetic patients: A systematic review and meta-analysis of the clinical evidence. Front Pharmacol. 2023;14:1132650.","journal-title":"Front Pharmacol"},{"key":"1922_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4172\/2155-6156.1000126","volume":"2","author":"P Fouqueray","year":"2011","unstructured":"Fouqueray P, Leverve X, Fontaine E, Baqui\u00e9 M, Wollheim C, Lebovitz H, et al. Imeglimin-a new oral anti-diabetic that targets the three key defects of type 2 diabetes. J Diabetes Metab. 2011;2:126.","journal-title":"J Diabetes Metab"},{"key":"1922_CR9","doi-asserted-by":"crossref","unstructured":"Tewari J, Qidwai KA, Tewari A, Rana A, Singh V, Tewari V et al. Efficacy and safety of imeglimin, a novel oral agent in the management of type 2 diabetes mellitus: a systematic review and meta-analysis. Naunyn Schmiedebergs Arch Pharmacol. 2025:1\u201313.","DOI":"10.1007\/s00210-025-04198-5"},{"key":"1922_CR10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ddr.21636","volume":"81","author":"R Yendapally","year":"2020","unstructured":"Yendapally R, Sikazwe D, Kim SS, Ramsinghani S, Fraser-Spears R, Witte AP, et al. A review of phenformin, metformin, and Imeglimin. Drug Dev Res. 2020;81:390\u2013401.","journal-title":"Drug Dev Res"},{"key":"1922_CR11","doi-asserted-by":"crossref","unstructured":"Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL et al. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes, Obesity and Metabolism. 2021;23:664\u2009\u2013\u200973.","DOI":"10.1111\/dom.14277"},{"key":"1922_CR12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/14656566.2020.1729123","volume":"21","author":"KS Johansson","year":"2020","unstructured":"Johansson KS, Br\u00f8nden A, Knop FK, Christensen MB. Clinical Pharmacology of Imeglimin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2020;21:871\u201382.","journal-title":"Expert Opin Pharmacother"},{"key":"1922_CR13","doi-asserted-by":"crossref","unstructured":"Higgins J. Cochrane handbook for systematic reviews of interventions. Cochrane Collaboration and John Wiley & Sons Ltd.; 2008.","DOI":"10.1002\/9780470712184"},{"key":"1922_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jclinepi.2021.09.021","volume":"141","author":"S Minozzi","year":"2022","unstructured":"Minozzi S, Dwan K, Borrelli F, Filippini G. Reliability of the revised Cochrane risk-of-bias tool for randomised trials (RoB2) improved with the use of implementation instruction. J Clin Epidemiol. 2022;141:99\u2013105.","journal-title":"J Clin Epidemiol"},{"key":"1922_CR15","doi-asserted-by":"crossref","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358.","DOI":"10.1136\/bmj.j4008"},{"key":"1922_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Res ed). 2008;336:924\u20136.","journal-title":"BMJ (Clinical Res ed)"},{"key":"1922_CR17","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1463-1326.2012.01611.x","volume":"14","author":"V Pirags","year":"2012","unstructured":"Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel Glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metabolism. 2012;14:852\u20138.","journal-title":"Diabetes Obes Metabolism"},{"key":"1922_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2337\/dc12-0453","volume":"36","author":"P Fouqueray","year":"2013","unstructured":"Fouqueray P, Pirags V, Inzucchi SE, Bailey CJ, Schernthaner G, Diamant M, et al. The efficacy and safety of Imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with Metformin monotherapy. Diabetes Care. 2013;36:565\u20138.","journal-title":"Diabetes Care"},{"key":"1922_CR19","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.2337\/dc13-2349","volume":"37","author":"P Fouqueray","year":"2014","unstructured":"Fouqueray P, Pirags V, Diamant M, Schernthaner G, Lebovitz HE, Inzucchi SE, et al. The efficacy and safety of Imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes Care. 2014;37:1924\u201330.","journal-title":"Diabetes Care"},{"key":"1922_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/dom.12452","volume":"17","author":"G Pacini","year":"2015","unstructured":"Pacini G, Mari A, Fouqueray P, Bolze S, Roden M. Imeglimin increases glucose-dependent insulin secretion and improves \u03b2\u2010cell function in patients with type 2 diabetes. Diabetes Obes Metabolism. 2015;17:541\u20135.","journal-title":"Diabetes Obes Metabolism"},{"key":"1922_CR21","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00228-020-02929-6","volume":"76","author":"J Dubourg","year":"2020","unstructured":"Dubourg J, Perrimond-Dauchy S, Felices M, Bolze S, Voiriot P, Fouqueray P. Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus. Eur J Clin Pharmacol. 2020;76:1393\u2013400.","journal-title":"Eur J Clin Pharmacol"},{"key":"1922_CR22","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2337\/dc20-0763","volume":"44","author":"J Dubourg","year":"2021","unstructured":"Dubourg J, Fouqueray P, Thang C, Grouin J-M, Ueki K. Efficacy and safety of Imeglimin monotherapy versus placebo in Japanese patients with type 2 diabetes (TIMES 1): a double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 3 trial. Diabetes Care. 2021;44:952\u20139.","journal-title":"Diabetes Care"},{"key":"1922_CR23","first-page":"e371","volume":"5","author":"P Theurey","year":"2022","unstructured":"Theurey P, Thang C, Pirags V, Mari A, Pacini G, Bolze S, Endocrinology, et al. Diabetes Metab. 2022;5:e371.","journal-title":"Diabetes Metab"},{"key":"1922_CR24","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/dom.14642","volume":"24","author":"C Reilhac","year":"2022","unstructured":"Reilhac C, Dubourg J, Thang C, Grouin JM, Fouqueray P, Watada H. Efficacy and safety of Imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): a randomized, double\u2010blind, placebo\u2010controlled phase 3 trial with a 36\u2010week open\u2010label extension period. Diabetes Obes Metabolism. 2022;24:838\u201348.","journal-title":"Diabetes Obes Metabolism"},{"key":"1922_CR25","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1111\/dom.16336","volume":"27","author":"K Kaku","year":"2025","unstructured":"Kaku K, Shimoda M, Osonoi T, Iwamoto M, Kaneto H. Efficacy and safety of Imeglimin add-on to DPP\u20104 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: an interim analysis of the randomised, double\u2010blind FAMILIAR trial. Diabetes Obes Metabolism. 2025;27:3212\u201322.","journal-title":"Diabetes Obes Metabolism"},{"key":"1922_CR26","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/dom.16086","volume":"27","author":"R Usui","year":"2025","unstructured":"Usui R, Hamamoto Y, Imura M, Omori Y, Yamazaki Y, Kuwata H, et al. Differential effects of Imeglimin and Metformin on insulin and incretin secretion\u2014An exploratory randomized controlled trial. Diabetes Obes Metabolism. 2025;27:856\u201365.","journal-title":"Diabetes Obes Metabolism"},{"key":"1922_CR27","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1111\/dom.16150","volume":"27","author":"A Takahashi","year":"2025","unstructured":"Takahashi A, Nomoto H, Yokoyama H, Yokozeki K, Furusawa S, Oe Y, et al. Efficacy of Imeglimin treatment versus Metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low\u2010dose Metformin: A multicenter, prospective, randomized, open\u2010label, parallel\u2010group comparison study (MEGMI study). Diabetes Obes Metabolism. 2025;27:1466\u201376.","journal-title":"Diabetes Obes Metabolism"},{"key":"1922_CR28","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/jdi.14070","volume":"14","author":"K Hagi","year":"2023","unstructured":"Hagi K, Nitta M, Watada H, Kaku K, Ueki K. Efficacy, safety and tolerability of Imeglimin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J Diabetes Invest. 2023;14:1246\u201361.","journal-title":"J Diabetes Invest"},{"key":"1922_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/17446651.2023.2290488","volume":"19","author":"H Permana","year":"2024","unstructured":"Permana H, Soetedjo NNM, Yanto TA, Tendean M, Hariyanto TI, Suastika K. Different doses of Imeglimin for management of type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-regression of randomized clinical trials. Expert Rev Endocrinol Metabolism. 2024;19:89\u201398.","journal-title":"Expert Rev Endocrinol Metabolism"},{"key":"1922_CR30","doi-asserted-by":"publisher","first-page":"102323","DOI":"10.1016\/j.dsx.2021.102323","volume":"15","author":"IA Abdelhaleem","year":"2021","unstructured":"Abdelhaleem IA, Salamah HM, Alsabbagh FA, Eid AM, Hussien HM, Mohamed NI, et al. Efficacy and safety of Imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials. Diabetes Metabolic Syndrome: Clin Res Reviews. 2021;15:102323.","journal-title":"Diabetes Metabolic Syndrome: Clin Res Reviews"},{"key":"1922_CR31","doi-asserted-by":"publisher","first-page":"102710","DOI":"10.1016\/j.dsx.2023.102710","volume":"17","author":"AK Singh","year":"2023","unstructured":"Singh AK, Singh A, Singh R, Misra A. Efficacy and safety of Imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials. Diabetes Metabolic Syndrome: Clin Res Reviews. 2023;17:102710.","journal-title":"Diabetes Metabolic Syndrome: Clin Res Reviews"},{"key":"1922_CR32","doi-asserted-by":"publisher","first-page":"100164","DOI":"10.1016\/j.deman.2023.100164","volume":"12","author":"P Vinayagam","year":"2023","unstructured":"Vinayagam P, Senathipathi V, Shivam V, Velraju N. The role of Imeglimin in glycemic control, beta cell function and safety outcomes in patients with type 2 diabetes mellitus: A comprehensive meta-analysis. Diabetes Epidemiol Manage. 2023;12:100164.","journal-title":"Diabetes Epidemiol Manage"},{"key":"1922_CR33","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/dom.14277","volume":"23","author":"S Hallakou-Bozec","year":"2021","unstructured":"Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, et al. Mechanism of action of imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021;23:664\u201373.","journal-title":"Diabetes Obes Metab"},{"key":"1922_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jdi.13669","volume":"13","author":"S Funazaki","year":"2022","unstructured":"Funazaki S, Yoshida M, Yamada H, Kakei M, Kawakami M, Nagashima S, et al. A novel mechanism of imeglimin-mediated insulin secretion via the cADPR-TRP channel pathway. J Diabetes Investig. 2022;13:34\u201341.","journal-title":"J Diabetes Investig"},{"key":"1922_CR35","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3390\/biology12050726","volume":"12","author":"H Yanai","year":"2023","unstructured":"Yanai H, Adachi H, Hakoshima M, Katsuyama H. Glucose-lowering effects of Imeglimin and its possible beneficial effects on diabetic complications. Biology. 2023;12:726.","journal-title":"Biology"}],"container-title":["Diabetology & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01922-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01922-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01922-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T03:50:43Z","timestamp":1757476243000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-025-01922-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1922"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01922-2","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"357"}}